[Effect of dibutyryl-cAMP on the cholesterol ester content in human atherosclerotic aorta cells].
Dibutyrly-cAMP (db-cAMP) reduces the content of cholesterol esters in intimal cells obtained from atherosclerotic areas of human aorta. This effect depends on the nucleotide concentration. Db-cAMP has no effect on the content of cholesterol esters in the cells obtained from unaffected aortic areas. It can be assumed that cAMP derivatives and agents that give rise to the increased cAMP level in the cells may impede the development of the atherosclerotic manifestation such as lipoidosis.
D000328:Adult; D001018:Aortic Diseases / Q000378:metabolism*; D001161:Arteriosclerosis / Q000378:metabolism*; D003994:Bucladesine / Q000494:pharmacology*; D002087:Butyrates / Q000494:pharmacology; D020148:Butyric Acid; D002788:Cholesterol Esters / Q000378:metabolism*; D003864:Depression, Chemical; D003995:Dibutyryl Cyclic GMP / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D008875:Middle Aged
D002087:Butyrates; D002788:Cholesterol Esters; D020148:Butyric Acid; D003995:Dibutyryl Cyclic GMP; D003994:Bucladesine
Vliianie dibutiril-tsAMF na soderzhanie éfirov kholesterina v kletkakh ateroskleroticheskoĭ aorty cheloveka.